36289848|t|Nephroprotective Properties of the Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) Receptor Agonists.
36289848|a|Diabetes mellitus is the leading cause of chronic kidney disease, and about 30-40% of patients with diabetes will develop kidney disease. Incretin hormones have received attention during the past three decades not only as a pharmacotherapy for the treatment of type 2 diabetes, but also for their cardiorenometabolic effects. The main incretins are glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Additional to the pancreas, receptors for GLP-1 are widely distributed in various organs, causing positive effects on endothelial function and vascular atherogenesis. Along with glycemic control and weight reduction, GLP-1 receptor agonists also strongly improve cardiovascular and renal outcomes in patients with type 2 diabetes. Recently, a dual GIP and GLP-1 receptor agonist has been approved for the treatment of type 2 diabetes. Compared to GLP-1 receptor agonist semaglutide, dual GIP and GLP-1 receptor agonist tirzepatide showed a superior reduction in hemoglobin A1c and body weight. Preliminary results also suggest that tirzepatide improves kidney outcomes in adults with type 2 diabetes with increased cardiovascular risk. In this review, we present the nephroprotective properties of dual GIP and GLP-1 receptor agonists as a new drug to treat type 2 diabetes.
36289848	35	79	Glucose-Dependent Insulinotropic Polypeptide	Gene	2695
36289848	81	84	GIP	Gene	2695
36289848	90	113	Glucagon-like Peptide-1	Gene	2641
36289848	115	120	GLP-1	Gene	2641
36289848	141	158	Diabetes mellitus	Disease	MESH:D003920
36289848	183	205	chronic kidney disease	Disease	MESH:D051436
36289848	227	235	patients	Species	9606
36289848	241	249	diabetes	Disease	MESH:D003920
36289848	263	277	kidney disease	Disease	MESH:D007674
36289848	402	417	type 2 diabetes	Disease	MESH:D003924
36289848	490	513	glucagon-like peptide-1	Gene	2641
36289848	515	520	GLP-1	Gene	2641
36289848	526	570	glucose-dependent insulinotropic polypeptide	Gene	2695
36289848	572	575	GIP	Gene	2695
36289848	620	625	GLP-1	Gene	2641
36289848	730	743	atherogenesis	Disease	MESH:D050197
36289848	795	809	GLP-1 receptor	Gene	2740
36289848	878	886	patients	Species	9606
36289848	892	907	type 2 diabetes	Disease	MESH:D003924
36289848	926	929	GIP	Gene	2695
36289848	934	948	GLP-1 receptor	Gene	2740
36289848	996	1011	type 2 diabetes	Disease	MESH:D003924
36289848	1025	1039	GLP-1 receptor	Gene	2740
36289848	1066	1069	GIP	Gene	2695
36289848	1074	1088	GLP-1 receptor	Gene	2740
36289848	1262	1277	type 2 diabetes	Disease	MESH:D003924
36289848	1381	1384	GIP	Gene	2695
36289848	1389	1403	GLP-1 receptor	Gene	2740
36289848	1436	1451	type 2 diabetes	Disease	MESH:D003924
36289848	Association	MESH:D003924	2695
36289848	Positive_Correlation	2695	2740
36289848	Association	MESH:D050197	2641
36289848	Negative_Correlation	MESH:D003924	2740

